By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics today said that it has completed the acquisition of Celera for around $671 million.

The Madison, NJ-based lab testing firm said that it completed the deal through a short-form merger after its tender offer expired last week. Each share of Celera common stock was converted into the right to receive the same $8 in cash, without interest and less any withholding of taxes, that was paid in the tender offer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.